Mission Bio Inc.
United States
18 articles with Mission Bio Inc.
-
Sequanta and Mission Bio announce strategic partnership
7/9/2021
Sequanta Technologies Co., Ltd. ("Sequanta") and Mission Bio. ("Mission Bio") are pleased to announce that they have entered into a strategic partnership, providing high-quality single-cell sequence services using Mission Bio's products to customers in mainland China .
-
Mission Bio's Tapestri Platform Used to Distinguish Acute Myeloid Leukemia Clones from CHIP Clones
5/25/2021
Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, announced a new peer-reviewed study published using the Tapestri Platform's single-cell multi-omics solution to accurately distinguish leukemic cells from clonal hematopoiesis of indeterminate potential in relapsed AML patients.
-
New Nature Study Uses Mission Bio's Tapestri Platform for Single-nuclei Sequencing of Solid Tissue
5/18/2021
The novel study showcases a cancer-like paradigm in cerebral cavernous malformations (CCM), a poorly understood, yet aggressive disease
-
Mission Bio just launched its Pharma Assay Development (PAD) service, enabling its customers to obtain early access services based on the newest technologies as well as on its existing products.
-
Mission Bio Launches Pharma Assay Development Services to Speed Access to New Technologies
4/20/2021
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the launch of its Pharma Assay Development services to accelerate biomarker discovery and cell and gene therapy development pipelines for biopharma customers.
-
Mission Bio Announces Yan Zhang as New CEO
4/8/2021
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the appointment of Yan Zhang to the role of CEO.
-
She succeeds Mission Bio’s current chief executive officer Charlie Silver, who will shift into an advisory role with the company he co-founded.
-
New Study Precisely Characterizes Tumor Heterogeneity in AML Patients Using Mission Bio's Tapestri Platform
3/11/2021
Validates multi-omics techniques for measuring therapeutic responses to AML, holding promise for future blood cancer treatments
-
Resistance Mechanisms to FLT3 Inhibitor for AML Characterized Using Mission Bio's Tapestri Platform in Newly Published Study
3/10/2021
Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, has announced that its Tapestri Platform was used in a new study published Friday in Blood Advances to characterize the complex clonal heterogeneity that leads to treatment resistance of the FLT3 inhibitor quizartinib in patients with acute myeloid leukemia.
-
Mission Bio’s Tapestri Platform is the first-ever single-cell multi-omics platform capable of identifying cancer cell mutation profiles.
-
First Commercial Platform with Mutations and CNV Insights from the Same Cell on Single Platform
8/22/2019
Today, Mission Bio announced the addition of Copy Number Analysis, which extends the platform’s Copy Number Variation capabilities without any change to the current workflow. -
BioSpace Movers and Shakers: April 26
4/26/2019
Companies strengthen leadership teams with C-suite and boards of directors appointments, with new hires at Sandoz, Mission Bio, SkinBio, Epic Sciences, and more. -
South San Francisco-based Mission Bio, the only company providing single-cell DNA sequencing, entered into a collaboration with LabCorp, to harness the abilities of the company’s Tapestri Platform to provide more precise clinical trials.
-
The San Francisco Business Times recently looked at top alumni from Bay Area incubators. Some of those companies are now brand-name companies like Uber and Reddit. Here’s a look at the biotech companies on their list.
-
Mission Bio Named a Winner of the 2018 Red Herring Top 100 North America Award
7/2/2018
Creators of the world’s leading platform for Precision Genomics chosen as one of the most promising and innovative companies
-
Mission Bio Debuts Custom Panels for Tapestri
2/6/2018
Mission Bio today announced the launch of Tapestri Custom Panels, an industry-first single-cell DNA capability that allows researchers and clinicians to focus on the genetic mutations most impactful to their research and patients.
-
Precision Medicine Meets Single-Cell DNA Analysis With Mission Bio
10/17/2017
Mission Bio, Inc., a pioneer in single-cell DNA analysis, today announced it has secured $10 million in Series A funding. Silicon Valley venture capital firm Mayfield Fund led the round.
-
Mission Bio Receives Investment From Life Science Angels
2/6/2017